Live feed01:05:00·1860dPRReleasevia QuantisnowNeuroRx Announces ZYESAMI™ (aviptadil, RLF-100) Met the Primary Endpoint of Its Phase 2b/3 Clinical Trial and Also Demonstrated a Meaningful Benefit in Survival from Critical COVID-19ByQuantisnow·Wall Street's wire, on your screen.BRPA· Big Rock Partners Acquisition Corp.FinanceOriginal source
